Abstract: As there are currently no absolute immunohistochemical positive markers for the definite diagnosis of malignant epithelioid mesothelioma, the identification of additional "positive" markers that may facilitate this diagnosis becomes of clinical importance. Therefore, the aim of this study was to identify novel positive markers of malignant mesothelioma. Whole genome gene expression analysis was performed using RNA extracted from formalin-fixed paraffin-embedded tissue sections of epithelioid mesothelioma and pulmonary adenocarcinoma. Gene expression analysis revealed that disabled homolog 2 (DAB2) and Intelectin-1 had significantly higher expression in epithelioid mesothelioma compared with that in pulmonary adenocarcinoma. The increased mRNA expression of DAB2 and Intelectin-1 was validated by reverse transcriptase polymerase chain reaction of RNA from tumor tissue and protein expression was validated by Western blotting of 5 mesothelioma cell lines. The utility of DAB2 and Intelectin-1 in the differential diagnosis of epithelioid mesothelioma and pulmonary adenocarcinoma was examined by an immunohistochemical study of 75 cases of epithelioid mesothelioma and 67 cases of pulmonary adenocarcinoma. The positive rates of DAB2 and Intelectin-1 expression in epithelioid mesothelioma were 80.0% and 76.0%, respectively, and 3.0% and 0%, respectively, in pulmonary adenocarcinoma. Immunohistochemically, the sensitivity and specificity of DAB2 was 80% and 97% and those of Intelectin-1 were 76% and 100% for differentiation of epithelioid mesothelioma from pulmonary adenocarcinoma. In conclusion, DAB2 and Intelectin-1 are newly identified positive markers of mesothelioma and have potential to be included in future immunohistochemical marker panels for differentiation of epithelioid mesothelioma from pulmonary adenocarcinoma.
M alignant mesothelioma is a rare and fatal malignant tumor. 1 In Japan, the mesothelioma death rate is increasing, approaching 1500 deaths in 2015, increased from 500 in 1995 according to Vital Statistics data published by the Ministry of Health, Labour and Welfare, Japan. 2 Similarly, the death rate due to mesothelioma is increasing globally, including the UK and Ireland, 3 the United States and other developing countries. 4 Asbestos exposure is the main risk factor for malignant pleural mesothelioma, including both occupational and environmental exposure. The time interval between first exposure to asbestos and diagnosis of mesothelioma is speculated to range from 20 to 50 years. Apart from the relatively long time it takes for asbestos to cause disease, delayed onset of symptoms can contribute to late-stage diagnosis and by then, the cancer spreads into the thoracic cavity and is more difficult to treat. Therefore, accurate diagnosis of mesothelioma is essential for its correct management.
A common site of origin of malignant mesothelioma is the pleura followed by other tissues including the peritoneum, pericardium, and tunica vaginalis. Malignant mesothelioma is classified into 3 major histologic subtypes: epithelioid, sarcomatoid, and biphasic as described in the 2015 World Health Organization (WHO) histologic classification of tumors of lung and pleura, 2015. 5 Epithelioid mesothelioma, which constitutes more than 60% of all mesothelioma, is the most common histologic subtype, and has a relatively better prognosis than sarcomatoid or biphasic mesothelioma. Epithelioid mesothelioma shows various histologic patterns including tubulopapillary, micropapillary, acinar, adenomatoid, and solid. As epithelioid mesothelioma closely resembles other malignant tumors showing pseudomesotheliomatous growth patterns, such as those of primarily lung carcinoma, breast carcinoma, and cancer that affects the lining of internal organs, the diagnosis of malignant mesothelioma is challenging, both histopathologically and clinically. Currently, the final diagnosis of malignant mesothelioma requires thorough reviewing of clinico-radiologic and pathologic findings (gross examination and histologic findings in tissue samples) with adequate immunohistochemical and/ or genetic analyses. As an immunohistochemical marker with absolute sensitivity and specificity is not yet available, the search for additional novel immunohistochemical markers is critical.
The aim of this study was to identify novel positive immunohistochemical markers by analysis of whole gene expression data using microarray gene chips. We performed gene expression analysis on epithelioid cells dissected from formalin-fixed paraffin-embedded (FFPE) tissue of epithelioid mesothelioma and pulmonary adenocarcinoma and identified several novel genes that are differentially expressed between epithelioid mesothelioma and pulmonary adenocarcinoma. Of these, we identified disabled homolog 2 (DAB2) and Intelectin-1 as potential novel positive immunohistochemical markers of epithelioid mesothelioma for differentiation from pulmonary adenocarcinoma.
MATERIALS AND METHODS

Patients and Histologic Samples
The materials included in this study were obtained from the archives of the Department of Pathology, Hiroshima University. The study group consisted of 75 patients with epithelioid mesothelioma who had undergone thoracoscopic pleural biopsy, pleurectomy/decortication, extrapleural pneumonectomy, or autopsy between 2000 and 2016. Between 2005 and 2016, 67 pulmonary adenocarcinoma cases were also obtained by thoracoscopic surgical segmentectomy or lobectomy of lung harboring adenocarcinoma. All microscopic slides were reviewed and reclassified using the current WHO histologic classification of tumors of lung and pleura, 2015 6 by 4 pathologists (M.K., K.K., V.J.A., and Y.T. 7 and current 2015 WHO histologic classification of tumors of the lung, pleura, thymus, and heart. 6 Anonymized tissue samples were provided by the Department of Pathology for gene expression and immunohistochemical analysis. This study was carried out in accordance with the Ethics Guidelines for Human Genome/Gene Research enacted by the Japanese Government for the collection of tissue specimens and was approved by the institutional ethics review committee (Hiroshima University E-974).
Gene Expression Analysis
Identification of Genes With Marked Difference Between Epithelioid Mesothelioma and Pulmonary Adenocarcinoma FFPE sections from 6 epithelioid mesothelioma cases and 6 pulmonary adenocarcinoma cases were used for gene expression analysis. RNA extraction for gene expression analysis was performed from papillary or solid growth of tumor cells in each specimen. Five 10 mm thick FFPE tumor tissue sections, each approximately 1 cm in diameter, were processed for total RNA extraction using the Maxwell RSC RNA FFPE Kit (Promega KK, Tokyo, Japan) according to the manufacturer's protocol. Briefly, after deparaffinization and lysis with proteinase K, the samples were treated with DNase I for 15 minutes at room temperature. Following this, RNA purification was carried out according to the manufacturer's protocol using a Maxwell RSC automation instrument (Promega KK). RNA quality check and quantification was performed as described previously 8 and RNA with an absorbance ratio of Z1.9 between 260 and 280 nm was used for microarray analysis. The Human Transcriptome 2.0 GeneChip Array (Affymetrix, Santa Clara, CA) containing gene transcript sets of 44,699 protein coding and 22,829 nonprotein coding clusters was used to analyze gene expression profiles. Total RNA was amplified and labeled with a 3 0 IVT Labeling Kit (Affymetrix) before hybridization onto the GeneChip. Briefly, 100 ng total RNA was amplified with GeneChip 3 0 IVT Pico kit (Affymetrix) to generate 30 mg of SenseRNA according to the manufacturer's protocol. SenseRNA (25 mg) was labeled with a 3 0 IVT Labeling Kit (Affymetrix) and hybridized to a Human Transcriptome 2.0 GeneChip (Affymetrix) as described previously. 8 The data were analyzed using the Gene Expression Console Software (Affymetrix), and further statistical analyses were performed using the Subio Software Platform (Subio, Amami-shi, Japan) to plot graphs and for fold change of expression and hierarchical clustering.
Validation of Gene Expression Analysis
Real-time Reverse Transcriptase Polymerase Chain Reaction
The same 6 cases of epithelioid mesothelioma and pulmonary adenocarcinoma that were analyzed for gene expression profiling were used to validate the microarray expression data by mRNA expression. The relative mRNA expression of DAB2 and Intelectin-1 was assessed with SYBR Green-based real-time reverse transcriptase polymerase chain reaction (RT-PCR) using GAPDH as a control. A total of 100 ng of RNA was used for mRNA expression with a VeryQuest SYBR Green 1-step RT-PCR Master Mix (Affymetrix) using a Stratagene Mx3000P qPCR System (Agilent Technologies, Santa Clara, CA). The primer pairs used for amplification of DAB2 and Intelectin-1 were DAB2-F: GTA GAA ACA AGT GCA ACC AAT GG, DAB2-R: GCC TTT GAA CCT TGC TAA GAG A, ITLN1-F: ACG TGC CCA ATA AGT CCC C, ITLN1-R: CCG TTG TCA GTC CAA CAC TTT C. Primers for GAPDH were GAPDH-F: ACA ACT TTG GTA TCG TGG AAG G, GAPDH-R: GCC ATC ACG CCA CAG TTT C. Data analysis was performed using the ddCT method for relative quantification. Briefly, threshold cycles (CT) for GAPDH (control) and DAB2 and Intelectin-1 (samples) were determined in triplicate. The relative expression (r I ) was calculated using the formula: r I = 2 À (CT sample À CT normal) .
Western Blotting
Total proteins were extracted from 5 commercially available mesothelioma cell lines (ACC-MESO-1, CRL-5915, ACC-MESO-4, CRL-5946, HMMME) using cell lysis protein extraction reagent (Cell-LyEX1 kit, TOYO B-Net, Tokyo, Japan). Approximately 25 mg of protein was subjected to electrophoresis on a Novex 10% Bis-Tris gel using a Bolt mini gel tank (Thermo Fisher Scientific, Yokohama, Japan). The proteins were then transferred to a Hybond-P PVDF membrane (GE Healthcare, Buckinghamshire, UK) using a Mini Blot Module (Thermo Fisher Scientific). After treating with blocking buffer, the transfer membrane was incubated with anti-DAB2 antibody (1:2000 rabbit polyclonal, catalog #HPA028888; Sigma-Aldrich, St. Louis, MO), anti-Human Intelectin-1 (1:2000, mouse monoclonal 3G9; Immuno-Biological Laboratories, Gunma, Japan) overnight at 41C. This was followed by streptavidin-labeled anti-mouse or antirabbit secondary antibodies (Cell Signaling Technology, Tokyo, Japan) and Immunostar LD (Wako Pure Chemicals, Tokyo, Japan) as a chemiluminescent detection reagent. Anti-GAPDH antibody (rabbit polyclonal, Santa Cruz Biotechnology, CA) was used as control. The blot membrane was captured by scanning with C-DiGit Blot Scanner (LI-COR) for detection of proteins of interest.
Immunohistochemical Procedures and Evaluation of Expression of DAB2 and Intelectin-1
Immunohistochemistry was performed using 3 mm tissue sections prepared from the best representative FFPE blocks of epithelioid mesothelioma and pulmonary adenocarcinoma cases. Immunohistochemical staining was performed using the Ventana Benchmark GX automated immunohistochemical station (Roche Diagnostics, Tokyo, Japan). Cell Condition buffer #1 at 951C for 32 minutes (Roche Diagnostics) was used for antigen retrieval. The sections were then incubated with primary antibodies to calretinin (rabbit monoclonal, SP65, prediluted; Roche Diagnostics), podoplanin (mouse monoclonal, D2-40, Prediluted; Nichirei Bioscience, Tokyo, Japan), Wilms' tumor gene product (WT1) (mouse monoclonal, 6F-H12, 1:25; Dako, Glostrup, Denmark), DAB2 (rabbit polyclonal, catalog #HPA028888, 1:200; Sigma-Aldrich), and Intelectin-1 (mouse monoclonal, 3G9, 1:1000; ImmunoBiological Laboratories). Incubation with the secondary antibody and detection was performed with Ventana ultraView Universal DAB Detection Kit.
Immunoreactivity
RESULTS
Differential Gene Expression and Validation in Epithelioid Mesothelioma and Pulmonary Adenocarcinoma
Of the 44,699 protein coding and 22,829 nonprotein coding transcripts on the Human Transcriptome 2.0 GeneChip Array, 902 statistically significant mRNA transcripts were differentially expressed, with a greater than 1.3-fold difference, between epithelioid mesothelioma and pulmonary adenocarcinoma (Fig. 1) . Hierarchical clustering of 426 protein coding mRNA transcripts revealed 197 upregulated mRNA transcripts in epithelioid mesothelioma, including CALB2, WT1, DAB2, and Intelectin-1, and 229 upregulated mRNA transcripts in pulmonary adenocarcinoma, including CEACAM6 and NAPSA ( Fig. 2 ; Supplementary Table S1, Supplemental Digital Content 1, http://links.lww.com/PAS/A504).
Real-time RT-PCR showed relative mRNA expression of DAB2 and Intelectin-1 was significantly higher in epithelioid mesothelioma than that in pulmonary adenocarcinoma (data not shown). Western blot analysis showed DAB2 and Intelectin-1 protein expression in all 5 commercially available mesothelioma cells lines with an electrophoretic band of 80 kDa with DAB2 and 1 or 2 electrophoretic bands in the range of 30 to 40 kDa with the Intelectin-1 antibody (Fig. 3) .
Immunohistochemical Expression Profiles in Epithelioid Mesothelioma and Pulmonary Adenocarcinoma
The expression of positive mesothelioma markers are summarized in Table 1 and the representative images for DAB2 and Intelectin-1 expression in epithelioid mesothelioma and pulmonary adenocarcinoma are pre-sented in Figures 4 and 5 , respectively. The staining pattern for each marker in 2 tumor types is described in the following sections.
DAB2 and Intelectin-1 Expression
The expression of DAB2 and Intelectin-1 was localized in the cytoplasm of tumor cells in epithelioid mesothelioma cases. Positive DAB2 expression was observed in 60 of 75 epithelioid mesotheliomas (80.0%) and 2 of 67 pulmonary adenocarcinomas (3.0%). In half of epithelioid mesotheliomas, DAB2 immunoreactivity was generally strong and diffuse (score 3+). In contrast, pulmonary adenocarcinomas showing DAB2 expression was focal (score 1+). In addition, DAB2 expression in alveolar macrophages in pulmonary adenocarcinomas was a helpful internal positive control. Positive Intelectin-1 expression was observed in 57 of 75 epithelioid mesotheliomas (76.0%), with most of them showing score 3+, whereas none of the 67 pulmonary adenocarcinomas were positive for Intelectin-1.
Calretinin, D2-40, and WT1 Expression
Positive calretinin expression was recorded for 74 of 75 epithelioid mesotheliomas (98.7%) and 17 of 67 pulmonary adenocarcinomas (25.4%). In epithelioid mesotheliomas, immunoreactivity was generally strong and diffuse (score 3+). In contrast, staining score in pulmonary adenocarcinomas was 1+ and 2+. There were no score 3+ cases in pulmonary adenocarcinomas. Positive D2-40 expression was observed in 71 of 75 epithelioid mesotheliomas (94.7%), with most of them showing score 3+, whereas only 7 pulmonary adenocarcinomas (10.4%) were focally positive (score 1+ and 2+) for D2-40. Positive WT1 expression was recorded in 62 of 75 epithelioid mesotheliomas (82.7%), whereas none of 67 pulmonary adenocarcinomas (0%) were positive for WT1.
Sensitivity and Specificity of Each Marker for Differential Diagnosis of Epithelioid Mesothelioma and Pulmonary Adenocarcinoma
The sensitivity and specificity of each marker for the differential diagnosis between epithelioid mesothelioma and pulmonary adenocarcinoma are shown in Table 2 . Sensitivity of Intelectin-1 (76%) was lowest among 5 positive markers; however, its specificity (100%) was absolute. Sensitivity (80.0%) and specificity (97.0%) of DAB2 were nearly those of WT1. Specificity of calretinin (74.6%) was lowest among 5 markers.
DISCUSSION
Pathologically, the role of immunohistochemistry in distinguishing pleural epithelioid mesothelioma from pulmonary adenocarcinoma has received much attention especially in the last 20 years. Currently, there are many immunohistochemical markers available for distinguishing epithelioid mesothelioma from pulmonary adenocarcinoma. Among these, calretinin, cytokeratin 5/6, podoplanin (D2-40), and WT1 are the preferred positive markers for epithelioid mesothelioma. Carcinoembryonic antigen (CEA), MOC31 (epithelial-related antigen), Ber-EP4, BG-8, thyroid transcription factor-1, claudin-4, and napsin-A are the preferred positive markers for pulmonary adenocarcinoma. The IMIG 2012 guidelines recommended the consideration of 2 mesothelial and 2 carcinoma markers, based on morphology at initial observation. 7 In practice, immunohistochemical examination, most laboratories use calretinin, D2-40, and WT1 for diagnosis of epithelioid mesothelioma. However, pathologists must interpret the results of staining by these markers carefully, as specificity of calretinin (74.6% in this study, 90% to 95% in IMIG 2012 guidelines) and D2-40 (88.9% in this study, up to 85% in IMIG 2012 guidelines) is not absolute; additionally, WT1 shows low sensitivity (82.7% in this study, approximately 90% to 100% in IMIG 2012 guidelines). Therefore, novel positive immunohistochemical markers, other than calretinin, D2-40, or WT1, are necessary for increasing the accuracy of epithelioid mesothelioma diagnosis.
Recent development of molecular techniques enabled gene expression analysis from RNA extracted from archival FFPE tumor tissues using GeneChip technology. This method is very useful to find new diagnostic markers, especially in rare tumors, including malignant mesothelioma. We have recently reported the identification of a novel marker, MUC4, for differentiating pleural sarcomatoid mesothelioma from pulmonary sarcomatoid carcinoma by analyzing gene expression data from a gene chip microarray. 8 In this study, we performed gene expression microarray analysis of 6 cases of mesothelioma and 6 cases of pulmonary adenocarcinoma to identify differentially expressed gene products in epithelioid mesothelioma and pulmonary adenocarcinoma. We found that the expression of DAB2 and Intelectin-1 in epithelioid mesothelioma was significantly higher than that in pulmonary adenocarcinoma and this was validated by real-time RT-PCR analysis of mRNA extracted from the same tissue source and Western blot analysis of proteins extracted from mesothelioma cell lines. Immunohistochemical analysis showed that expression of DAB2 and Intelectin-1 in epithelioid mesotheliomas was significantly higher than that in pulmonary adenocarcinomas. These novel positive mesothelial markers, DAB2 and/or Intelectin-1, contribute in accurate mesothelioma diagnosis, in addition to known positive markers (calretinin, D2-40, and WT1). In the present study, we analyzed gene expression analysis of only 6 cases of epithelioid mesothelioma and 6 cases of pulmonary adenocarcinoma, and found many differentially expressed genes mentioned in Supplementary Table S1 (Supplemental Digital Content 1, http://links.lww.com/ PAS/A504). As the analysis of substantially larger number will make these findings more credible, we plan to include more cases in the future.
DAB2, a mitogen-responsive phosphoprotein, is expressed in normal ovarian epithelial cells, but is downregulated or absent from ovarian carcinoma cell lines, suggesting its role as a tumor suppressor. 9 Decreased DAB2 expression has been reported in various human cancers, including esophageal, 10 lung, 11 ovarian, 9 prostate, 12 and breast 13 cancers. DAB2 downregulation in these cancers were reported partly due to miRNA targeting DAB2 10, 14 or promoter hypermethylation. 13, 15 However, the biological significance or expression of DAB2 has not yet been reported in malignant mesothelioma. In the present study, we found increased expression of DAB2 in epithelioid mesothelioma compared with that in pulmonary adenocarcinoma by gene expression microarray analysis. We also confirmed this increased expression of DAB2 in epithelioid mesothelioma by real-time RT-PCR and western blot. From the differential analysis of DAB2 expression between epithelioid mesothelioma and pulmonary adenocarcinoma by immunohistochemical study, we found higher sensitivity and specificity in epithelioid mesothelioma of >80%. In 2 of the 67 cases of pulmonary adenocarcinoma, DAB2 expression was identified in tumor cells but with a low immunoreactivity score. DAB2 expression in pulmonary adenocarcinomas was present in inflammatory cell infiltration, mainly macrophages; therefore, precaution must be taken by the physician when interpreting pulmonary adenocarcinoma results for DAB2 expression. Human Intelectin-1, also known as omentin, is a galactose-binding lectin that is usually expressed in the heart and small intestine as a host defense lectin that binds to bacterial galactofuranose. 16 Intelectin-1 is mainly expressed in the intestinal goblet cells and omentum, and occasionally in the thymus, bronchus, heart, liver, kidney collecting tubule cells, bladder umbrella, and mesothelial cells. 17 Recently, the overexpression of Intelectin-1 in human malignant pleural mesothelioma and its secretion into pleural effusions indicated toward it being a potential biomarker. 17, 18 It was reported that Intelectin-1 was not expressed in various cancers, except in some mucusproducing adenocarcinomas. 19 In the present study, we observed high expression of Intelectin-1 mRNA in epithelioid mesothelioma, definite expression of Intelectin-1 in mesothelioma cell lines by western blot analysis, and in 57 of 75 mesothelioma tissue samples by immunohistochemical analysis. In addition, we also found Intelectin-1 expression in non-neoplastic mesothelial lining cells and goblet cells in bronchi and bronchioles (data not shown). No Intelectin-1 expression was recorded in any pulmonary adenocarcinoma cases, confirming its potential as a novel positive mesothelial marker. The functional roles of DAB2 and Intelectin-1 expression in epithelioid mesothelioma need further analysis, which is beyond the scope of this study.
In conclusion, we identified 2 novel positive markers of epithelioid mesothelioma, DAB2 and Intelectin-1, by using gene expression microarray analysis and confirmed their utility to differentiate epithelioid mesothelioma from 
